Table 4.

Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Rate of Screening and Compliance

Control Group	Percentage
Rate of PSA screening in control group
Year 1	40
Year 6	52
Rate for those having undergone no more than 1 PSA test at baseline (89%)
Year 1	33
Year 6	46
Rate of DRE screening	41–46
Screening Group
Compliance in the screening group
Vital stats known, 7 years (% baseline population)	98
Vital stats known, 10 years (% baseline population)	67
PSA compliance	85
DRE compliance	86

DRE, digital rectal examination; PSA, prostate-specific antigen.

Data from Andriole GL et al.²